Estrogen Therapy in 2017
- 297 Downloads
Purpose of Review
After the publication of the Women’s Health Initiative, there was a dramatic reduction in prescriptions for menopausal hormonal therapy (MHT). We performed a literature search and reviewed major society guidelines to discuss recommendations and practice since 2010 regarding MHT.
While not recommended for management and prevention of chronic diseases, MHT offers relief for bothersome menopausal symptoms. For vasomotor symptoms and vaginal atrophy, low-dose estrogen therapy (systemic and vaginally, respectively) provided effective relief of symptoms and improved quality of life. For cognitive and mood related effects, MHT had little benefit.
Consideration of MHT for menopausal symptoms should be part of an overall strategy including lifestyle recommendations regarding diet, exercise, smoking cessation, and safe levels of alcohol consumption for maintaining the health of peri- and postmenopausal women. Future research should examine best practices for tapering therapy and monitoring for endometrial cancer risk.
KeywordsEstrogen therapy Estrogen replacement Menopausal symptoms Hot flashes Vaginal atrophy
Compliance with Ethical Standards
Conflict of Interest
Drs Sylvestre & Kim have no conflicts of interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Anderson G, Limacher M. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initative randomized controlled trial. JAMA. 2004;294(14):1701–12.Google Scholar
- 7.•• Hodis H, Mack W, Henderson V, Shoupe D, Budoff M, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374:1221–31. This randomized trial demonstrated that randomization to transdermal estradiol had little impact on coronary artery calcification, suggesting that estradiol therapy might not increase risk of cardiovascular disease events.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Gold E, Colvin A, Avis N, Bromberger J, Greendale G, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition; study of women’s health across the nation. Am J Public Health. 2006;96(7):1226–35.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Demetrio F, Renno JJ, Gianfaldoni A, Goncalves M, Halbe H, Filho A, et al. Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women: a randomized double-blind, controlled study. Arch Womens Ment Health. 2011;14(6):479–86.CrossRefPubMedGoogle Scholar
- 33.• Archer D, Pickar J, MacAllister D, Warren M. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause. 2012;19(6):622–9. This double-blind, randomized, placebo-controlled, multicenter, 12-week trial aimed to determine the efficacy, safeter, and lowest practical dose of a transdermal estradiol gel in the treatment of symptomatic postmenopausal women. The study assessed the frequency of moderate to severe hot flushes at 4 and 12 weeks of therapy.CrossRefPubMedGoogle Scholar
- 34.• Veerus P, Hovi S, Sevon T, Hunter M, Hemminki E. The effect of homrone therapy on women’s quality of life in the first year of the Estonian Postmenopausal Hormone Therapy Trial. BMC Res Notes. 2012;5:176. This randomized trial aimed to analyze the impact of hormonal therapy on different aspects of symptom experience and quality of life. Women were randomized into three different treatment arms and one non-treatment arms. This study confirms the use of hormone therapy for the management of menopausal symptoms.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Caan B, LaCroix A, Joffe H, Guthrie K, Larson J, Carpenter J, et al. Effects of estrogen or venlafaxine on menopause related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause. 2015;22(6):607–15.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Illston J, Wheeler T, Parker C, Conner M, Burgio K, Goode P, et al. Low-dose 17-beta-estradiol cream for vaginal atrophy in a cohort without prolapse: serum levels and vaginal response including tissue biomarkers associated with tissue remodeling. Maturitas. 2015;81(4):475–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.NG Clearinghouse. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Rockville: Agency for Healthcare Research and Quality (AHRQ); 2013. Available from: https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society.